Affiliation:
1. Institute of Social Medicine and Epidemiology, University of Luebeck, 23562 Luebeck, Germany
2. Institute of Cancer Epidemiology, University of Luebeck, 23562 Luebeck, Germany
Abstract
(1) Background: Screen-detected breast cancer patients tend to have better survival than patients diagnosed with symptomatic cancer. The main driver of improved survival in screen-detected cancer is detection at earlier stage. An important bias is introduced by lead time, i.e., the time span by which the diagnosis has been advanced by screening. We examine whether there is a remaining survival difference that could be attributable to mode of detection, for example, because of higher quality of care. (2) Methods: Women with a breast cancer (BC) diagnosis in 2000–2022 were included from a population-based cancer registry from Schleswig-Holstein, Germany, which also registers the mode of cancer detection. Mammography screening was available from 2005 onwards. We compared the survival for BC detected by screening with symptomatic BC detection using Kaplan–Meier, unadjusted Cox regressions, and Cox regressions adjusted for age, grading, and UICC stage. Correction for lead time bias was carried out by assuming an exponential distribution of the period during which the tumor is asymptomatic but screen-detectable (sojourn time). We used a common estimate and two recently published estimates of sojourn times. (3) Results: The analysis included 32,169 women. Survival for symptomatic BC was lower than for screen-detected BC (hazard ratio (HR): 0.23, 95% confidence interval (CI): 0.21–0.25). Adjustment for prognostic factors and lead time bias with the commonly used sojourn time resulted in an HR of 0.84 (CI: 0.75–0.94). Using different sojourn times resulted in an HR of 0.73 to 0.90. (4) Conclusions: Survival for symptomatic BC was only one quarter of screen-detected tumors, which is obviously biased. After adjustment for lead-time bias and prognostic variables, including UICC stage, survival was 27% to 10% better for screen-detected BC, which might be attributed to BC screening. Although this result fits quite well with published results for other countries with BC screening, further sources for residual confounding (e.g., self-selection) cannot be ruled out.
Reference33 articles.
1. (2024, January 11). Krebs—Krebs in Deutschland—Krebs in Deutschland für 2019/2020. Available online: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_inhalt.html.
2. Stage at Diagnosis Is a Key Explanation of Differences in Breast Cancer Survival across Europe;Sant;Int. J. Cancer,2003
3. Breast Cancer Survival and Stage at Diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000–2007: A Population-Based Study;Walters;Br. J. Cancer,2013
4. Implementation of the German Mammography Screening Program (German MSP) and First Results for Initial Examinations, 2005–2009;Malek;Breast Care,2016
5. Vor- und Nachteile des Mammographie-Screenings;Onkologe,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献